These therapies primarily target immune checkpoint proteins located on the surface of tumor cells, such as Programmed Death-1 (PD-1) and Cytotoxic T lymphocyte-associated protein 4 (CTLA-4). The gene discussed is CTLA4; the disease is neoplasm.